Literature DB >> 9586638

Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules.

S Le Gall1, L Erdtmann, S Benichou, C Berlioz-Torrent, L Liu, R Benarous, J M Heard, O Schwartz.   

Abstract

The surface expression of MHC I is reduced in HIV-infected cells. We show that the Nef protein affects the intracellular sorting of HLA-A and -B molecules. In the presence of Nef, these proteins accumulate in the Golgi and colocalize with clathrin-coated vesicles. MHC I modulation relies on a tyrosine-based sorting signal located in the cytoplasmic domain of HLA-A and -B heavy chains. This cryptic sorting signal becomes operative only in the presence of Nef. Nef interacts with the medium (mu) subunit of AP adaptor complexes involved in the recognition of tyrosine-based sorting signals, likely facilitating the connection between MHC I and the clathrin-dependent sorting machinery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586638     DOI: 10.1016/s1074-7613(00)80553-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  151 in total

1.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.

Authors:  V Piguet; L Wan; C Borel; A Mangasarian; N Demaurex; G Thomas; D Trono
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

3.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation.

Authors:  S Le Gall; F Buseyne; A Trocha; B D Walker; J M Heard; O Schwartz
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 8.  Lessons from viral manipulation of protein disposal pathways.

Authors:  Margo H Furman; Hidde L Ploegh
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

9.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

10.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.